Dare Bioscience, Inc.
Daré Bioscience, Inc. (Nasdaq Capital Market: DARE) is a purpose-driven health biotech company solely focused on closing gaps in women's health between promising science and real-world solutions. The company develops and commercializes evidence-based products across multiple therapeutic areas including contraception,… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Dare Bioscience, Inc. does
In the company’s own words
Daré Bioscience, Inc. (Nasdaq Capital Market: DARE) is a purpose-driven health biotech company solely focused on closing gaps in women's health between promising science and real-world solutions. The company develops and commercializes evidence-based products across multiple therapeutic areas including contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health, and menopause.
Daré operates through a dual-path business model that combines traditional FDA-approved products with alternative regulatory pathways. The company's first FDA-approved product, XACIATO (clindamycin phosphate) vaginal gel 2%, received approval in December 2021 for treating bacterial vaginosis. In 2022, Daré licensed exclusive worldwide commercialization rights to Organon, which made the product available nationwide in the United States in January 2024. To fund pipeline development, Daré monetized its royalty and milestone payment rights from XACIATO sales through an agreement with XOMA.
In March 2025, Daré expanded its business model to include Section 503B compounding, enabling earlier market access for select proprietary formulations through FDA-registered outsourcing facilities. The company's first 503B product, DARE to PLAY Sildenafil Cream, initiated commercialization in December 2025 as a topical formulation designed to improve female sexual arousal. DARE to RECLAIM, an intravaginal ring delivering bioidentical estradiol and progesterone for menopausal hormone therapy, is targeted for early 2027 availability.
The company also launched a consumer health product line called DARE to RESTORE, with Flora Sync LF5, a vaginal probiotic suppository, expected to become available in the second quarter of 2026. Daré's clinical-stage pipeline includes Ovaprene, a hormone-free monthly intravaginal contraceptive currently in pivotal Phase 3 trials, and Sildenafil Cream 3.6% for female sexual arousal disorder treatment.
Daré has received non-dilutive funding from U.S. federal government agencies and private foundations to support development of eight programs. The company operates without its own sales force or distribution infrastructure, instead leveraging strategic partnerships with third-party manufacturers, telehealth providers, and dispensing pharmacies. The DARE Health Hub serves as the branded online platform for prescription processing and patient communications. More information is available at www.darebioscience.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1401914
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Dare Bioscience, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Dare Bioscience, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Dare Bioscience, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Dare Bioscience, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Dare Bioscience, Inc.'s last four quarterly filings that the numbers alone won't show?”